

Currently released so far... 51122 / 251,287
Articles
Brazil
Sri Lanka
United Kingdom
Sweden
00. Editorial
United States
Latin America
Egypt
Jordan
Yemen
Thailand
Browse latest releases
2010/12/01
2010/12/02
2010/12/03
2010/12/04
2010/12/05
2010/12/06
2010/12/07
2010/12/08
2010/12/09
2010/12/10
2010/12/11
2010/12/12
2010/12/13
2010/12/14
2010/12/15
2010/12/16
2010/12/17
2010/12/18
2010/12/19
2010/12/20
2010/12/21
2010/12/22
2010/12/23
2010/12/24
2010/12/25
2010/12/26
2010/12/27
2010/12/28
2010/12/29
2010/12/30
2011/01/01
2011/01/02
2011/01/04
2011/01/05
2011/01/07
2011/01/09
2011/01/11
2011/01/12
2011/01/13
2011/01/14
2011/01/15
2011/01/16
2011/01/17
2011/01/18
2011/01/19
2011/01/20
2011/01/21
2011/01/22
2011/01/23
2011/01/24
2011/01/25
2011/01/26
2011/01/27
2011/01/28
2011/01/29
2011/01/30
2011/01/31
2011/02/01
2011/02/02
2011/02/03
2011/02/04
2011/02/05
2011/02/06
2011/02/07
2011/02/08
2011/02/09
2011/02/10
2011/02/11
2011/02/12
2011/02/13
2011/02/14
2011/02/15
2011/02/16
2011/02/17
2011/02/18
2011/02/19
2011/02/20
2011/02/21
2011/02/22
2011/02/23
2011/02/24
2011/02/25
2011/02/26
2011/02/27
2011/02/28
2011/03/01
2011/03/02
2011/03/03
2011/03/04
2011/03/05
2011/03/06
2011/03/07
2011/03/08
2011/03/09
2011/03/10
2011/03/11
2011/03/13
2011/03/14
2011/03/15
2011/03/16
2011/03/17
2011/03/18
2011/03/19
2011/03/20
2011/03/21
2011/03/22
2011/03/23
2011/03/24
2011/03/25
2011/03/26
2011/03/27
2011/03/28
2011/03/29
2011/03/30
2011/03/31
2011/04/01
2011/04/02
2011/04/03
2011/04/04
2011/04/05
2011/04/06
2011/04/07
2011/04/08
2011/04/09
2011/04/10
2011/04/11
2011/04/12
2011/04/13
2011/04/14
2011/04/15
2011/04/16
2011/04/17
2011/04/18
2011/04/19
2011/04/20
2011/04/21
2011/04/22
2011/04/23
2011/04/24
2011/04/25
2011/04/26
2011/04/27
2011/04/28
2011/04/29
2011/04/30
2011/05/01
2011/05/02
2011/05/03
2011/05/04
2011/05/05
2011/05/06
2011/05/07
2011/05/08
2011/05/09
2011/05/10
2011/05/11
2011/05/12
2011/05/13
2011/05/14
2011/05/15
2011/05/16
2011/05/17
2011/05/18
2011/05/19
2011/05/20
2011/05/21
2011/05/22
2011/05/23
2011/05/24
2011/05/25
2011/05/26
2011/05/27
2011/05/28
2011/05/29
2011/05/30
2011/05/31
2011/06/01
2011/06/02
2011/06/03
2011/06/04
2011/06/05
2011/06/06
2011/06/07
2011/06/08
2011/06/09
2011/06/10
2011/06/11
2011/06/12
2011/06/13
2011/06/14
2011/06/15
2011/06/16
2011/06/17
2011/06/18
2011/06/19
2011/06/20
2011/06/21
2011/06/22
2011/06/23
2011/06/24
2011/06/25
2011/06/26
2011/06/27
2011/06/28
2011/06/29
2011/06/30
2011/07/01
2011/07/02
2011/07/04
2011/07/05
2011/07/06
2011/07/07
2011/07/08
2011/07/10
2011/07/11
2011/07/12
2011/07/13
2011/07/14
2011/07/15
2011/07/16
2011/07/17
2011/07/18
2011/07/19
2011/07/20
2011/07/21
2011/07/22
2011/07/23
2011/07/25
2011/07/27
2011/07/28
2011/07/29
2011/07/31
2011/08/01
2011/08/02
2011/08/03
2011/08/05
2011/08/06
2011/08/07
2011/08/08
2011/08/09
2011/08/10
2011/08/11
2011/08/12
2011/08/13
2011/08/15
2011/08/16
2011/08/17
2011/08/18
2011/08/19
2011/08/21
2011/08/22
2011/08/23
2011/08/24
Browse by creation date
Browse by origin
Embassy Athens
Embassy Asuncion
Embassy Astana
Embassy Asmara
Embassy Ashgabat
Embassy Apia
Embassy Antananarivo
Embassy Ankara
Embassy Amman
Embassy Algiers
Embassy Addis Ababa
Embassy Accra
Embassy Abuja
Embassy Abu Dhabi
Embassy Abidjan
Consulate Auckland
Consulate Amsterdam
Consulate Alexandria
Consulate Adana
American Institute Taiwan, Taipei
Embasy Bonn
Embassy Bujumbura
Embassy Buenos Aires
Embassy Budapest
Embassy Bucharest
Embassy Brussels
Embassy Bridgetown
Embassy Brazzaville
Embassy Bratislava
Embassy Brasilia
Embassy Bogota
Embassy Bishkek
Embassy Bern
Embassy Berlin
Embassy Belmopan
Embassy Belgrade
Embassy Beirut
Embassy Beijing
Embassy Banjul
Embassy Bangui
Embassy Bangkok
Embassy Bandar Seri Begawan
Embassy Bamako
Embassy Baku
Embassy Baghdad
Consulate Belfast
Consulate Barcelona
Embassy Cotonou
Embassy Copenhagen
Embassy Conakry
Embassy Colombo
Embassy Chisinau
Embassy Caracas
Embassy Canberra
Embassy Cairo
Consulate Curacao
Consulate Ciudad Juarez
Consulate Chiang Mai
Consulate Chennai
Consulate Chengdu
Consulate Casablanca
Consulate Cape Town
Consulate Calgary
Embassy Dushanbe
Embassy Dublin
Embassy Doha
Embassy Djibouti
Embassy Dili
Embassy Dhaka
Embassy Dar Es Salaam
Embassy Damascus
Embassy Dakar
DIR FSINFATC
Consulate Dusseldorf
Consulate Durban
Consulate Dubai
Consulate Dhahran
Embassy Guatemala
Embassy Grenada
Embassy Georgetown
Embassy Gaborone
Consulate Guayaquil
Consulate Guangzhou
Consulate Guadalajara
Embassy Helsinki
Embassy Harare
Embassy Hanoi
Consulate Hong Kong
Consulate Ho Chi Minh City
Consulate Hermosillo
Consulate Hamilton
Consulate Hamburg
Consulate Halifax
Embassy Kyiv
Embassy Kuwait
Embassy Kuala Lumpur
Embassy Kolonia
Embassy Kinshasa
Embassy Kingston
Embassy Kigali
Embassy Khartoum
Embassy Kathmandu
Embassy Kampala
Embassy Kabul
Consulate Krakow
Consulate Kolkata
Consulate Karachi
Embassy Luxembourg
Embassy Lusaka
Embassy Luanda
Embassy London
Embassy Lome
Embassy Ljubljana
Embassy Lisbon
Embassy Lima
Embassy Lilongwe
Embassy Libreville
Embassy La Paz
Consulate Leipzig
Consulate Lahore
Consulate Lagos
Mission USOSCE
Mission USNATO
Mission UNESCO
Mission Geneva
Embassy Muscat
Embassy Moscow
Embassy Montevideo
Embassy Monrovia
Embassy Mogadishu
Embassy Minsk
Embassy Mexico
Embassy Mbabane
Embassy Maseru
Embassy Maputo
Embassy Manila
Embassy Manama
Embassy Managua
Embassy Malabo
Embassy Madrid
Consulate Munich
Consulate Mumbai
Consulate Montreal
Consulate Monterrey
Consulate Milan
Consulate Merida
Consulate Melbourne
Consulate Matamoros
Consulate Marseille
Embassy Nouakchott
Embassy Nicosia
Embassy Niamey
Embassy New Delhi
Embassy Ndjamena
Embassy Nassau
Embassy Nairobi
Consulate Nuevo Laredo
Consulate Naples
Consulate Naha
Consulate Nagoya
Embassy Pristina
Embassy Pretoria
Embassy Praia
Embassy Prague
Embassy Port Of Spain
Embassy Port Moresby
Embassy Port Louis
Embassy Port Au Prince
Embassy Podgorica
Embassy Phnom Penh
Embassy Paris
Embassy Paramaribo
Embassy Panama
Consulate Peshawar
REO Hillah
REO Basrah
Embassy Rome
Embassy Riyadh
Embassy Riga
Embassy Reykjavik
Embassy Rangoon
Embassy Rabat
Consulate Rio De Janeiro
Consulate Recife
Secretary of State
Embassy Suva
Embassy Stockholm
Embassy Sofia
Embassy Skopje
Embassy Singapore
Embassy Seoul
Embassy Sarajevo
Embassy Santo Domingo
Embassy Santiago
Embassy Sanaa
Embassy San Salvador
Embassy San Jose
Consulate Surabaya
Consulate Strasbourg
Consulate St Petersburg
Consulate Shenyang
Consulate Shanghai
Consulate Sapporo
Consulate Sao Paulo
Embassy Tunis
Embassy Tripoli
Embassy Tokyo
Embassy Tirana
Embassy The Hague
Embassy Tel Aviv
Embassy Tehran
Embassy Tegucigalpa
Embassy Tbilisi
Embassy Tashkent
Embassy Tallinn
Consulate Toronto
Consulate Tijuana
Consulate Thessaloniki
USUN New York
USMISSION USTR GENEVA
USEU Brussels
US Office Almaty
US Mission Geneva
US Mission CD Geneva
US Interests Section Havana
US Delegation, Secretary
UNVIE
UN Rome
Embassy Ulaanbaatar
Embassy Vilnius
Embassy Vientiane
Embassy Vienna
Embassy Vatican
Embassy Valletta
Consulate Vladivostok
Consulate Vancouver
Browse by tag
AMGT
ASEC
AEMR
AR
APECO
AU
AORC
ADANA
AJ
AF
AFIN
AMED
AS
AM
ABLD
AFFAIRS
AMB
APER
ACOA
AND
AA
AE
AADP
AID
AO
AL
AG
AORD
ADM
AINF
AINT
ASEAN
AORG
ABT
APEC
AY
ASUP
ARF
AGOA
AVIAN
ATRN
ANET
AGIT
ASECVE
ABUD
AODE
ALOW
ADB
AN
ADPM
ASPA
ARABL
AFSN
AZ
AC
AIAG
AFSI
ASCE
ASIG
ACABQ
ADIP
AFGHANISTAN
AROC
ADCO
ACOTA
ANARCHISTS
AMEDCASCKFLO
AK
ARABBL
ASCH
ANTITERRORISM
AGRICULTURE
AOCR
ARR
ASSEMBLY
AORCYM
AFPK
ACKM
AGMT
AEC
APRC
AIN
AFPREL
ASFC
ASECTH
AFSA
AINR
AOPC
AFAF
AFARI
AX
ASECAF
ASECAFIN
AT
AFZAL
APCS
AGAO
AIT
ARCH
AEMRASECCASCKFLOMARRPRELPINRAMGTJMXL
AMEX
ARM
AQ
ATFN
AMBASSADOR
AORCD
AVIATION
ARAS
AINFCY
ACBAQ
AOPR
AREP
AOIC
ASEX
ASEK
AER
AGR
AMCT
AVERY
APR
AEMRS
AFU
AMG
ATPDEA
ASECKFRDCVISKIRFPHUMSMIGEG
AORL
ACS
AMCHAMS
AECL
AUC
ACAO
BA
BR
BB
BG
BEXP
BY
BRUSSELS
BU
BD
BTIO
BK
BL
BE
BMGT
BO
BM
BX
BN
BWC
BBSR
BTT
BC
BH
BILAT
BUSH
BHUM
BT
BTC
BMENA
BOND
BAIO
BP
BF
BRPA
BURNS
BUT
BBG
BCW
BOEHNER
BOL
BASHAR
BIDEN
BFIN
BZ
BEXPC
BTIU
CPAS
CA
CASC
CS
CBW
CIDA
CO
CODEL
CI
CROS
CU
CH
CWC
CMGT
CVIS
CDG
CTR
CG
CF
CHIEF
CJAN
CBSA
CE
CY
CB
CW
CM
CHR
CD
COE
CV
COUNTER
CT
CN
CPUOS
CTERR
CVR
CVPR
CDC
COUNTRY
CLEARANCE
CONS
COM
CACS
CR
CONTROLS
CAN
CACM
COMMERCE
CAMBODIA
CFIS
COUNTERTERRORISM
CITES
CONDOLEEZZA
CZ
CTBT
CEN
CLINTON
CFED
CARC
CTM
CARICOM
CSW
CICTE
CYPRUS
CBE
CMGMT
CARSON
CWCM
CIVS
COUNTRYCLEARANCE
CENTCOM
CAPC
COPUOS
CKGR
CITEL
CQ
CITT
CIC
CARIB
CVIC
CAFTA
CVISU
CDB
CEDAW
CNC
CJUS
COMMAND
CENTER
COL
CAJC
CONSULAR
CLMT
CBC
CIA
CNARC
CIS
CEUDA
CHINA
CAC
CL
DR
DJ
DEMOCRATIC
DEMARCHE
DOMESTIC
DISENGAGEMENT
DB
DA
DHS
DAO
DCM
DAVID
DO
DEAX
DEFENSE
DEA
DTRO
DPRK
DOC
DTRA
DK
DAC
DOD
DRL
DRC
DCG
DE
DOT
DEPT
DOE
DS
DKEM
ECON
ETTC
EFIS
ETRD
EC
EMIN
EAGR
EAID
EFIN
EUN
ECIN
EG
EWWT
EINV
ENRG
ELAB
EPET
EIND
EN
EAIR
EUMEM
ECPS
ES
EI
ELTN
ET
EZ
EU
ER
EINT
ENGR
ECONOMIC
ENIV
EFTA
ETRN
EMS
EUREM
EPA
ESTH
EEB
EET
ENV
EAG
EXIM
ECTRD
ELNT
ENVIRONMENT
ECA
EAP
EINDIR
ETR
ECONOMY
ETRC
ELECTIONS
EICN
EXPORT
EARG
EGHG
EID
ETRO
EINF
EAIDHO
ECIP
EENV
EURM
EPEC
ERNG
ENERG
EIAD
EXBS
ED
EREL
ELAM
EK
EWT
ENGRD
EDEV
ECE
ENGY
EXIMOPIC
ETRDEC
ECCT
EUR
ENRGPARMOTRASENVKGHGPGOVECONTSPLEAID
EFI
ECOSOC
EXTERNAL
ESCAP
ETCC
EENG
ERA
ENRD
ECLAC
ETRAD
EBRD
ENVR
ECONENRG
ELTNSNAR
ELAP
EPIT
EDUC
EAIDXMXAXBXFFR
EETC
EIVN
EDRC
EGOV
ETRA
EAIDRW
ETRDEINVECINPGOVCS
ESA
ETRDGK
ENVI
ELN
EPRT
EPTED
ERTD
EUM
EAIDS
EFINECONEAIDUNGAGM
EDU
EV
EAIDAF
EDA
EPREL
EINVEFIN
EAGER
ETMIN
EUCOM
ECCP
EIDN
EINVKSCA
ENNP
EFINECONCS
ETC
EAIRASECCASCID
EINN
ETRP
ECONOMICS
ENERGY
EIAR
EINDETRD
ECONEFIN
EURN
ETRDEINVTINTCS
EFIM
ETIO
EATO
EIPR
EINVETC
ETTD
ETDR
EIQ
ECONCS
ENRGIZ
EAIG
ENTG
EUC
ERD
EINVECONSENVCSJA
EEPET
EUNCH
ESENV
ECINECONCS
ETRDECONWTOCS
ECUN
FR
FI
FOREIGN
FARM
FIR
FAO
FK
FARC
FAS
FJ
FREEDOM
FAC
FINANCE
FBI
FTAA
FM
FCS
FAA
FORCE
FDA
FTA
FT
FCSC
FMGT
FINR
FIN
FDIC
FOR
FOI
FO
FMLN
FISO
GM
GERARD
GT
GA
GG
GR
GTIP
GH
GZ
GE
GB
GY
GAZA
GJ
GEORGE
GOI
GCC
GMUS
GI
GLOBAL
GV
GC
GL
GOV
GKGIC
GF
GWI
GIPNC
GUTIERREZ
GTMO
GANGS
GAERC
GUILLERMO
GASPAR
HR
HA
HYMPSK
HO
HK
HUMAN
HU
HN
HHS
HURI
HUD
HUMRIT
HUMANITARIAN
HUMANR
HL
HSTC
HILLARY
HCOPIL
HADLEY
HOURANI
HI
HUM
HEBRON
HUMOR
IZ
IN
IAEA
IS
IMO
ILO
IR
IC
IT
ITU
ID
IV
IMF
IBRD
IWC
ICAO
ICRC
INF
IO
IPR
ISO
IK
ISRAELI
IQ
ICES
IDB
INFLUENZA
IRAQI
ISCON
IGAD
IRAN
ITALY
IRAQ
ICTY
ICTR
ITPGOV
ITALIAN
IQNV
IADB
INTERNAL
INMARSAT
IRDB
ILC
INCB
INRB
ICJ
ISRAEL
INR
IEA
ISPA
ICCAT
IOM
ITRD
IHO
IL
IFAD
ITRA
IDLI
ISCA
INL
INRA
INTELSAT
ISAF
ISPL
IRS
IEF
ITER
INDO
IIP
IND
IEFIN
IACI
IAHRC
INNP
IA
INTERPOL
IFIN
ISSUES
IZPREL
IRAJ
IF
ITPHUM
ITA
IP
IRPE
IDA
ISLAMISTS
ITF
INRO
IBET
IDP
IRC
KMDR
KPAO
KOMC
KNNP
KFLO
KDEM
KSUM
KIPR
KFLU
KE
KCRM
KJUS
KAWC
KZ
KSCA
KDRG
KCOR
KGHG
KPAL
KTIP
KMCA
KCRS
KPKO
KOLY
KRVC
KVPR
KG
KWBG
KTER
KS
KN
KSPR
KWMN
KV
KTFN
KFRD
KU
KSTC
KSTH
KISL
KGIC
KSEP
KFIN
KTEX
KTIA
KUNR
KCMR
KCIP
KMOC
KTDB
KBIO
KBCT
KMPI
KSAF
KACT
KFEM
KPRV
KPWR
KIRC
KCFE
KRIM
KHIV
KHLS
KVIR
KNNNP
KCEM
KLIG
KIRF
KNUP
KSAC
KNUC
KPGOV
KTDD
KIDE
KOMS
KLFU
KNNC
KMFO
KSEO
KJRE
KJUST
KMRS
KSRE
KGIT
KPIR
KPOA
KUWAIT
KIVP
KICC
KSCS
KPOL
KSEAO
KRCM
KSCI
KNAP
KGLB
KICA
KCUL
KPRM
KFSC
KQ
KPOP
KPFO
KPALAOIS
KREC
KBWG
KR
KTTB
KNAR
KCOM
KESS
KINR
KOCI
KWN
KCSY
KREL
KTBT
KFTN
KW
KRFD
KFLOA
KHDP
KNEP
KIND
KHUM
KSKN
KOMO
KDRL
KTFIN
KSOC
KPO
KGIV
KSTCPL
KSI
KPRP
KFPC
KNNB
KNDP
KICCPUR
KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG
KDMR
KFCE
KIMMITT
KMCC
KMNP
KSEC
KOMCSG
KGCC
KRAD
KCRP
KAUST
KWAWC
KCHG
KRDP
KPAS
KTIAPARM
KPAOPREL
KWGB
KIRP
KMIG
KLAB
KSEI
KHSA
KNPP
KPAONZ
KWWW
KGHA
KY
KCRIM
KCRCM
KGCN
KPLS
KIIP
KPAOY
KTRD
KTAO
KJU
KBTS
KWAC
KFIU
KNNO
KPAI
KILS
KPA
KRCS
KWBGSY
KNPPIS
KNNPMNUC
KNPT
KERG
KLTN
KPREL
KTLA
KO
KAWK
KVRP
KAID
KX
KENV
KWCI
KNPR
KCFC
KNEI
KFTFN
KTFM
KCERS
KDEMAF
KMEPI
KEMS
KBTR
KEDU
KIRL
KNNR
KMPT
KPDD
KPIN
KDEV
KFRP
KTBD
KMSG
KWWMN
KWBC
KA
KOM
KWNM
KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG
KRGY
KNNF
KICR
KIFR
KWMNCS
KPAK
KDDG
KCGC
KID
KNSD
KMPF
KWMM
MARR
MX
MASS
MOPS
MNUC
MCAP
MTCRE
MRCRE
MTRE
MASC
MY
MK
MG
MU
MILI
MO
MZ
MEPP
MCC
MEDIA
MOPPS
MI
MAS
MW
MP
MEPN
MV
MD
MR
MC
MCA
MT
MIL
MARITIME
MOPSGRPARM
MAAR
MOOPS
ML
MA
MN
MNUCPTEREZ
MTCR
MUNC
MPOS
MONUC
MGMT
MURRAY
MACP
MINUSTAH
MCCONNELL
MGT
MNUR
MF
MEPI
MOHAMMAD
MAR
MAPP
MNU
MFA
MTS
MLS
MEETINGS
MERCOSUR
MED
MNVC
MIK
MBM
MILITARY
MAPS
MARAD
MDC
MACEDONIA
MASSMNUC
MUCN
MQADHAFI
MPS
NZ
NATO
NI
NO
NU
NG
NL
NPT
NS
NA
NP
NASA
NSF
NEA
NANCY
NSG
NRR
NATIONAL
NMNUC
NC
NSC
NAS
NARC
NELSON
NATEU
NDP
NIH
NK
NIPP
NR
NERG
NSSP
NE
NTDB
NT
NEGROPONTE
NGO
NATOIRAQ
NAR
NZUS
NCCC
NH
NAFTA
NEW
NRG
NUIN
NOVO
NATOPREL
NV
NICHOLAS
NPA
NSFO
NW
NORAD
NPG
NOAA
OPRC
OPDC
OTRA
OECD
OVIP
OREP
ODC
OIIP
OAS
OSCE
OPIC
OMS
OFDP
OFDA
OEXC
OPCW
OIE
OSCI
OM
OPAD
ODPC
OIC
ODIP
OPPI
ORA
OCEA
OREG
OMIG
OFFICIALS
OSAC
OEXP
OPEC
OFPD
OAU
OCII
OIL
OVIPPRELUNGANU
OSHA
OPCD
OPCR
OF
OFDPQIS
OSIC
OHUM
OTR
OBSP
OGAC
OESC
OVP
ON
OES
OTAR
OCS
PREL
PGOV
PARM
PINR
PHUM
PM
PREF
PTER
PK
PINS
PBIO
PHSA
PE
PBTS
PA
PL
POL
PAK
POV
POLITICS
POLICY
PO
PRELTBIOBA
PKO
PIN
PNAT
PU
PGOVPREL
PALESTINIAN
PTERPGOV
PELOSI
PAS
PP
PTEL
PROP
PRELAF
PRHUM
PRE
PUNE
PIRF
PVOV
PROG
PERSONS
PROV
PKK
PRGOV
PH
PLAB
PDEM
PCI
PRL
PRM
PINSO
PERM
PETR
PPAO
PERL
PBS
PETERS
PRELBR
PCON
POLITICAL
PMIL
POLM
PKPA
PNUM
PLO
PTERM
PJUS
PARMP
PNIR
PHUMKPAL
PG
PREZ
PGIC
PAO
PROTECTION
PRELPK
PGOVENRG
PATTY
PSOC
PARTIES
PGOVEAIDUKNOSWGMHUCANLLHFRSPITNZ
PMIG
PAIGH
PARK
PETER
PHUS
PKPO
PGOVECON
POUS
PMAR
PWBG
PAR
PGOVGM
PHUH
PTE
PY
POLUN
PDOV
PGOVSOCI
PGOVPM
PRELEVU
PGOR
PBTSRU
PHUMA
PHUMR
PPD
PGV
PRAM
PARMS
PINL
PSI
PKPAL
PPA
PTERE
PGOF
PINO
PREO
PHAS
PAC
PRESL
PORG
PS
PGVO
PKFK
PSOE
PEPR
PINT
PRELP
PREFA
PNG
PTBS
PFOR
PGOVLO
PHUMBA
PREK
PHJM
POLINT
PGOVE
PHALANAGE
PARTY
PECON
PEACE
PROCESS
PLN
PEDRO
PF
PGPV
PCUL
PGGV
PSA
PGOVSMIGKCRMKWMNPHUMCVISKFRDCA
PGIV
PHUMPREL
POGOV
PEL
PBT
PAMQ
PINF
PSEPC
POSTS
PAHO
PHUMPGOV
PGOC
PNR
RS
RP
RU
RW
RFE
RCMP
RIGHTSPOLMIL
REFORM
RO
ROW
ROBERT
REACTION
REPORT
REGION
RELATIONS
RAY
ROBERTG
RIGHTS
RM
RATIFICATION
RREL
RBI
RICE
ROOD
REL
RODHAM
RGY
RUEHZO
RELIGIOUS
RELFREE
RUEUN
RELAM
RSP
RF
REO
REGIONAL
RUPREL
RI
REMON
RPEL
RSO
SCUL
SENV
SOCI
SZ
SNAR
SO
SP
SU
SY
SI
SMIG
SYR
SA
SW
SF
SR
SYRIA
SNARM
START
SPECIALIST
SG
SNIG
SCI
SGWI
SE
SIPDIS
SANC
SELAB
SN
SETTLEMENTS
SCIENCE
SENVENV
SENS
SPCE
SPAS
SECURITY
SENC
SOCIETY
SOSI
SENVEAGREAIDTBIOECONSOCIXR
SEN
SPECI
ST
SL
SENVCASCEAIDID
SC
SECRETARY
STR
SNA
SOCIS
SADC
SEP
SK
SHUM
SYAI
SMIL
STEPHEN
SNRV
SKCA
SENSITIVE
SECI
SCUD
SCRM
SGNV
SECTOR
SAARC
SENVSXE
SWMN
STEINBERG
SOPN
SOCR
SCRS
SWE
SARS
SNARIZ
SUDAN
SENVQGR
SAN
SM
SFNV
SSA
SPCVIS
SOFA
SCULKPAOECONTU
SENVKGHG
SHI
SEVN
SH
SNARCS
SNARN
SIPRS
TBIO
TW
TRGY
TSPA
TU
TPHY
TI
TX
TH
TIP
TSPL
TNGD
TZ
TS
TC
TK
TURKEY
TERRORISM
TPSL
TINT
TRSY
TERFIN
TPP
TT
TECHNOLOGY
TE
TAGS
TRAFFICKING
TJ
TN
TO
TD
TP
TREATY
TR
TA
TIO
TECH
TF
TRAD
TNDG
TWI
TPSA
TWL
TAUSCHER
TRBY
TL
TV
THPY
TSPAM
TREL
TRT
TNAR
TFIN
TWCH
THOMMA
THOMAS
TERROR
TRY
TBID
UK
UNESCO
UNSC
UNGA
UN
US
UZ
USEU
UG
UP
UNAUS
UNMIK
USTR
UY
USUN
UNEP
UNDC
UV
UNPUOS
UNSCR
USAID
UNODC
UNRCR
UNHCR
UNDP
UNCRIME
UA
UNHRC
UNRWA
UNO
UNCND
UNCHR
USAU
UNICEF
USPS
UNOMIG
UNESCOSCULPRELPHUMKPALCUIRXFVEKV
UR
UNFICYP
UNCITRAL
UNAMA
UNVIE
USTDA
USNC
UNCSD
USCC
UNEF
UNGAPL
USSC
UNMIC
UNTAC
UNCLASSIFIED
USDA
UNCTAD
USGS
UNFPA
UNSE
USOAS
UE
UAE
UNCHS
UNDESCO
UNC
UNSCS
UKXG
UNGACG
UNHR
UNBRO
UNCHC
UNFCYP
UNIDROIT
WHTI
WIPO
WTRO
WHO
WTO
WMO
WFP
WEET
WS
WE
WA
WHA
WBG
WILLIAM
WI
WSIS
WCL
WEBZ
WZ
WW
WWBG
WMD
WWT
WMN
WWARD
WITH
WTRQ
WCO
WEU
WB
WBEG
Browse by classification
Community resources
courage is contagious
Viewing cable 08TAIPEI572, Taiwan Pharma: Slower Approvals, Lower Prices
If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs
Understanding cables
Every cable message consists of three parts:
- The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
- The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
- The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #08TAIPEI572.
Reference ID | Created | Released | Classification | Origin |
---|---|---|---|---|
08TAIPEI572 | 2008-04-24 22:27 | 2011-08-23 00:00 | UNCLASSIFIED//FOR OFFICIAL USE ONLY | American Institute Taiwan, Taipei |
VZCZCXRO9109
PP RUEHC
DE RUEHIN #0572/01 1152227
ZNR UUUUU ZZH
P 242227Z APR 08 ZDK
FM AIT TAIPEI
TO RUEHC/SECSTATE WASHDC PRIORITY 8756
INFO RUEHOO/CHINA POSTS COLLECTIVE
RUEHHK/AMCONSUL HONG KONG 9433
UNCLAS SECTION 01 OF 05 TAIPEI 000572
SIPDIS
STATE PLEASE PASS TO AIT/W AND EAP/RSP/TC
STATE PASS USTR/DKATZ AND USTR/JRAGLAND
USDOC FOR 4430/ITA/MAC
SENSITIVE
SIPDIS
E.O. 12958: N/A
TAGS: ETRD ECON TW
SUBJECT: Taiwan Pharma: Slower Approvals, Lower Prices
REF: 2007 Taipei 2326
TAIPEI 00000572 001.2 OF 005
Summary
-------
1.(SBU) A slow and complex drug approval and pricing process in
Taiwan limits drug choices for patients and reduces potential
profits for U.S. pharmaceutical firms. New drugs are often not
available in Taiwan until more than two years after the drug has
been available in the United States. Taiwan reimbursement prices
are falling so much that a number of U.S. and other foreign
original-drug manufacturers have pulled drugs off the market. To
make matters worse, other countries are beginning to reference
Taiwan's low reimbursement prices when setting drug-reimbursement
prices in their own healthcare systems, magnifying the potential for
increased losses for U.S. firms. Representatives of foreign
pharmaceutical firms point to inadequate funding for the national
health insurance system as the fundamental problem with
pharmaceutical prices, but are pessimistic that the authorities will
raise healthcare budgets anytime soon. Taiwan's healthcare system
has a cumulative USD 1.6-billion deficit. Taiwan's Department of
Health estimates this deficit could reach USD four billion by 2015,
while our pharmaceutical-industry contacts estimate it will increase
to USD six billion by 2012. End summary.
Three-step Process Slows Time to Market
---------------------------------------
¶2. (SBU) Introducing a new drug--or adding new medical use for an
already-approved drug--to Taiwan's National Health Insurance (NHI)
reimbursement list is a lengthy three-step process. First, the
Center for Drug Evaluations (CDE), a quasi-official committee that
reports to the Department of Health (DOH) Bureau of Pharmaceutical
Affairs (BOPA), must evaluate the safety and efficacy of the drug,
and pass its recommendation to BOPA. U.S. drug companies tell us
that, even under the faster track for drugs already approved by the
U.S. FDA, the CDE takes two to three months from the time of
application to begin consideration of a new drug, after which the
CDE will usually need several more meetings over another two to
three months to review the new drug's clinical trial results and
other data. During this process, the CDE often asks drug companies
for more information on some aspect of the drug's safety or
efficacy, slowing the process further. After the CDE passes its
recommendation to BOPA's approval committee, BOPA reviews the CDE
decision, and often asks companies for further information before
finally granting approval for the drug's use in Taiwan. Finally,
the DOH Bureau of National Health Insurance (BNHI) then takes about
six months to evaluate and assign a reimbursement price to the
drug.
¶3. (SBU) According to original-drug manufacturers, the problem is
not only the sluggishness of the approval process, but also the
process' unpredictability. Our contacts tell us that they cannot
anticipate what sorts of data or other trial information the CDE or
BOPA's committee will ask for, nor can drug-makers reliably predict
how long it will take either to make a decision. Peter Wang,
President and Managing Director of Wyeth Taiwan, complained recently
to econoff that "policy seems to change day by day." Wang said the
CDE or BOPA will reject a drug for a myriad of often-unpredictable
reasons, and each agency will often ask for further information or
additional trials, slowing down the approval process by two to three
months with each request.
¶4. (SBU) Original-drug manufacturers in Taiwan also claim that the
authorities have become less willing to accept drug-trial results
and other documentation from outside Taiwan. For example, for drugs
manufactured in Europe, Taiwan formerly accepted a certificate of
approval from either E.U. or U.S. regulatory authorities in order to
fast-track the drug for domestic use. Taiwan, however, now requires
certification from both, which usually results in a delay while the
company waits for the approval process to finish in the United
States. Je Hwa Park, Managing Director for Janssen-Cilag (JC)
Taiwan, recently told us that in the past, Taiwan's drug-approval
authorities waived bridging studies--supplemental studies performed
in Taiwan to provide clinical data on the efficacy, safety, and
dosage specifically for the Taiwan market--for about 85 percent of
all drugs, but that this has fallen to 45 percent since 2004.
Sometimes, even a bridging study is not enough. According to Park,
in one recent case, the CDE required JC to re-start the testing and
trial process for a new anti-cancer drug, while the Korean
regulatory authorities asked only for a bridging study for the same
drug.
¶5. (SBU) BOPA Director General Chi-chou Liao, however, recently told
TAIPEI 00000572 002.2 OF 005
econoff that the agency's licensing and approval process has not
gotten any slower for most new drugs, nor did he think that BOPA has
significantly increased requests for supplemental studies. Liao did
comment, however, that BOPA has become more aware in recent years
that the effectiveness of some drugs changes due to ethnic
differences between people in Taiwan and the test subjects of most
clinical studies done outside of Taiwan. For example, Liao noted,
BOPA has found that a lung cancer drug that was withdrawn from the
U.S. market as ineffective is in fact very effective for Taiwanese
lung cancer patients. Due to cases such as this, BOPA will sometimes
ask for additional studies that include Taiwanese or Chinese
patients.
¶6. (SBU) After the CDE and BOPA approve a drug for use in Taiwan,
BNHI begins the process of assigning a reimbursement price for the
drug. Although BNHI usually takes about six months to assign a
price, original drug manufacturers say that the initial price is
usually much lower than the median price in the group of 10 advanced
economies (A10) that the pharmaceutical industry uses as a worldwide
price benchmark, which comprises the United States, Canada,
Australia, New Zealand, France, Germany, Italy, Sweden, Switzerland,
and Belgium. Since the initial price is usually lower than what the
companies are willing to accept, in most cases they appeal the BNHI
decision, setting the six-month process in motion again, and
prolonging the pricing process to one year. In a recent meeting
with econoff, BNHI Vice President Cheng-hua put the blame for long
price-assignation processes on drug companies for appealing "again
and again" for higher prices after BNHI has set an initial price.
Lee noted that tight BNHI budgets have forced the agency to set
initial prices that are in many cases lower than what drug firms
expect, but added that most new drugs introduced into Taiwan are not
"breakthrough" drugs, and that drug companies should therefore not
expect prices for such drugs to be close to the A10 average.
¶7. (SBU) Chang Ly-yun, Chairwoman of Taiwan's only NGO focusing on
overall healthcare reform, the Taiwan Health Reform Foundation
(THRF), told econoff on April 17 that tight BNHI budgets have indeed
prompted the Bureau to set low initial drug prices. She blamed the
budget woes on both inadequate funding for the Taiwan healthcare
system, as well as BNHI's failure to remove older, less-effective
pharmaceuticals from its 10,000-drug reimbursement list. Continuing
to reimburse hospitals for dispensing older drugs, she maintains,
saps money that could be available to pay more for newer, more
effective medicines. Chang suggested hospitals may be prescribing
these older medicines less for their medical effectiveness and more
out of either habit, or in order to raise hospital revenues from the
difference between the lower prices hospitals have negotiated with
drug companies and the higher amounts that BNHI reimburses for the
same drugs.
¶8. (SBU) In any case, according to drug-industry figures, the
average time for the approval plus pricing processes has increased
to at least two years from an average of one year earlier this
decade. Wyeth's Wang said that, in his company's experience,
getting a drug to market in Taiwan now takes from two to 2.5 years.
Janssen-Cilag's Park recently told econoff that, due to slower
approvals and pricing times, JC launches new products in Taiwan from
one to two years behind South Korea, where he says approvals have
sped up over the past two years. Park blames both BNHI for what he
characterizes as its slow and unsatisfactory pricing decisions, as
well as the separate--and sometimes conflicting--review processes at
BOPA and CDE. He accused BOPA and CDE bureaucrats of creating new,
ad-hoc approval hurdles to increase their agency's power and prove
how "patriotic" they are by "linking approval to reducing the
financial burden on the healthcare system instead of healthcare
need." This translates to a situation where, in many cases, Taiwan
patients must wait two or more years after the drugs have been
approved for the U.S. market.
Low Prices Reducing Market's Appeal
-----------------------------------
¶9. (SBU) Original-drug manufacturers' difficulties don't end when
they finally get a BNHI reimbursement rate for a new drug, since the
initial price is, in most cases, continually reduced by BNHI's
biannual price-volume surveys (PVSs). Since individual hospitals
negotiate drug prices directly with drug companies, BNHI conducts
PVSs to ascertain the average price that Taiwan's hospitals are
paying for each drug, and then adjusts the reimbursement rate. After
each PVS, hospitals typically re-negotiate contracts with drug
companies in order to push the price down again, since hospitals
rely heavily on revenues derived from the difference between the
prices they have negotiated with drug companies and the higher
amounts that BNHI reimburses for the same drugs--the source of the
TAIPEI 00000572 003 OF 005
so-called "Black Hole" in Taiwan's pharmaceuticals budget (reftel).
¶10. (SBU) The result of this continual downward price pressure is
that, according to estimates by original-pharmaceutical
manufacturers, average prices for on-patent drugs in Taiwan are 40
percent below the A10 median. According to Jordan Ter, Managing
Director for Merck, Sharpe and Dohme Taiwan (MSD), low profits for
original-drug manufacturers have reduced Taiwan from one of the
region's most attractive markets to one of the least over the past
five years. MSD and other drug makers tell us that their
projections show Taiwan will be the lowest-growth market for
original drugs in East Asia over the next five years.
¶11. (SBU) Ter is also pessimistic about the long-term market for
original-drug makers in Taiwan. He recently told econoff that
Taiwan is less and less important to MSD headquarters, which focuses
instead on other regional markets such as Japan, China, and,
increasingly, South Korea, which he says offers both a larger market
and a better business and R&D environment. He hopes that Taiwan will
become an easier place for drug companies to do business after a new
administration takes office in May, but for now he is worried that
his headquarters' recent trend of reducing both sales and research
funding in the Taiwan market will continue.
¶12. (SBU) According to Janssen-Cilag's Park, Singapore, Korea,
Thailand, and China are now competitive with Taiwan in drug trials,
and since his company's funding for trials tends to correlate with
sales, he believes that the company will continue a relative shift
of spending on research and trials into other markets. Park said
although absolute investment in the Taiwan market has been steady
over the past few years, the company's investment in Taiwan relative
to other regional markets is less than it should be considering
Taiwan's research capabilities.
¶13. (SBU) David Lin, Country Manager for Pfizer Taiwan, told econoff
recently that slowing sales have caused a two-year decline in the
company's business in Taiwan. However, Lin said Pfizer--unlike
other foreign drug makers in Taiwan--separates its view of a
market's sales potential from decisions on where to invest its
research and testing dollars. According to Lin, Pfizer continues to
increase testing and research spending in Taiwan due to the high
quality of Taiwan's research hospitals and universities.
Low Prices Pushing Drugs Out of Market
--------------------------------------
¶14. (SBU) Taiwan's low reimbursement rates are not just hurting
companies' sales figures, but are also driving drugs out of the
domestic market. In some cases, successive price-volume surveys
reduce the BNHI reimbursement price to such a low level that
pharmaceutical companies stop selling the drug in Taiwan. According
to Ter, MSD has already pulled several drugs from the Taiwan market.
MSD has pulled drugs from other markets in the region as
well--including New Zealand--and Ter said that the company will not
hesitate to continue doing so in any market where the price drops
below cost. According to David Lin, in 2007 alone, Pfizer stopped
selling 10 of its total Taiwan line of 90 drugs for this reason.
Janssen-Cilag and Wyeth also both told us that they have dropped
products from the Taiwan market for the same reason.
¶15. (SBU) Sometimes the difference between Taiwan's reimbursement
price and the international market price can put firms in an awkward
position of considering pulling potentially life-saving drugs from
the market. In the case of the Pfizer product Solu-cortef, which is
used in ambulances and emergency rooms for treating acute
tuberculosis and severe allergic reactions, the company decided in
early 2007 to remove the drug from the Taiwan market after the last
PVS reduced the BNHI reimbursement price to 28 NT/vial, well below
the international market price of 130 NT/vial. The company decided
to phase the drug out over 2007 in order to give customers time to
adjust. In December 2007, however, hospitals notified Pfizer that
the drug is "essential" and cannot be supplied by local generic-drug
manufacturers, and asked the company to continue selling the drug in
Taiwan. Pfizer then notified BNHI that the company will not be able
to supply Solu-cortef to Taiwan unless BNHI moves quickly to
re-adjust its reimbursement price to at least 75 NT/vial.
BNHI, however, has not moved to expedite the price review, meaning
that the Bureau will not start consideration of this price
readjustment until late April, with a final decision unlikely until
August. Pfizer has not decided what to do, but told econoff that if
BNHI does take until summer to decide, Pfizer will stop selling the
drug in Taiwan.
TAIPEI 00000572 004.2 OF 005
Defensive Moves to Drop Drugs from Market
-----------------------------------------
¶16. (SBU) Foreign drug companies in Taiwan also express concern that
countries in the region are starting to reference BNHI's
reimbursement prices when setting drug-reimbursement prices in their
own healthcare systems. According to several companies'
representatives, in 2007, Korea started to set Taiwan reimbursement
prices as target prices for original-drug manufacturers' products in
Korea. Wyeth's Wang said that China and Thailand were also starting
to reference Taiwan's prices--which are both attractively low and
also clearly posted on the BNHI website--when determining their own
domestic drug prices. Wang warned that if this continues, Wyeth
would consider removing drugs from the Taiwan market--even
profitable ones--as a defensive measure to avoid losing money in
other markets. JC's Park said that the company has already pulled
products out of Taiwan for this reason, and echoed Wyeth's concerns
about other countries using Taiwan's reimbursement prices to set
prices in their own markets.
Low Healthcare Budget Is Root of Problem
----------------------------------------
¶17. (SBU) Representatives of foreign pharmaceutical firms all point
to inadequate funding for national healthcare as the fundamental
problem with BNHI pharmaceutical pricing. According to healthcare
experts in Taiwan, per-capita monthly premiums and visit co-pays are
roughly half of those in South Korea, which has a national
health-insurance system of similar scope and age as Taiwan's
(reftel). As a result, Taiwan's National Healthcare Insurance (NHI)
system has a cumulative deficit of USD 1.6-billion. Our
pharmaceutical-industry contacts estimate this figure will increase
to USD six billion by 2012, and BNHI itself estimated in 2005 that
the NHI deficit would reach USD four billion by 2015 if premiums are
not raised. Because of the healthcare system's budget woes, both
public and private hospitals are severely underfunded, and therefore
make up shortfalls in the difference between the lower prices they
have negotiated with drug companies and the higher amounts that BNHI
reimburses them for the same drugs. According to BOPA Director
General Chi-chou Liao, hospitals derive up to half of their
operating profits from this difference. To ensure that this price
gap remains as high as possible, hospitals--which are by far the
drug companies' largest customers in Taiwan--constantly negotiate
with drug companies to push prices down.
¶18. (SBU) Wyeth's Wang believes that, due to Taiwan's relatively low
healthcare spending, delaying the next PVS or implementing standard
contracts for all hospitals would provide only temporary relief to
original-drug manufacturers. JC's Park agrees that implementing
mandatory standard contracts will not make a difference as long as
the budget does not grow, and told econoff that the only long-term
solution is either to cut back on healthcare services or persuade
the Taiwan public that it will need to pay more to enjoy the current
level of health care.
¶19. (SBU) Most of our private-sector interlocutors, however, are
pessimistic that Taiwan's leaders have the political will to make
such efforts. Instead, they project that in the short and medium
terms, BNHI will continue to try to control costs by reducing
reimbursement prices for original drugs, and hospitals will continue
to re-negotiate drug prices whenever this happens. Although
Pfizer's Lin thinks policymakers and voters in Taiwan are smart
enough to fix the budget problem before a true crisis arrives, he
worries electoral pressures will continue to put the fear of rate
hikes into the average politician and bureaucrat. JC's Park sounded
the only note of optimism among the U.S. firms, recently telling
econoff he believes that 2008 in Taiwan could be the year voters
decide that without an increase in funding and a decrease in some
coverage, the healthcare system will begin to falter.
Comment
-------
¶20. (SBU) Taiwan's National Health Insurance system is hugely
popular and provides a relatively high level of care at low prices
to virtually everyone in Taiwan. Unfortunately the system is not
sustainable at current funding levels, it delays access to the
newest medicines, and greatly reduces potential profits for U.S.
firms. The United States may want to widen the topics discussed
under TIFA pharma working groups to include ways to speed up
pharmaceutical approvals in Taiwan. We will be engaging with the
CDE, BOPA, and BNHI over the near future to express our concerns
about the drug approval and pricing process. As for increasing BNHI
spending on drugs, foreign pharmaceutical firms may have domestic
TAIPEI 00000572 005.2 OF 005
allies in doctors and the hospitals that they work for, which form
the most powerful domestic medical interest group (see reftel for
more information). End comment.